CHF0.0015 close: IGPH.SW stock most active on SIX 06 Jan 2026: liquidity note
IGPH.SW stock closed at CHF0.0015 on SIX on 06 Jan 2026 after a -25.00% intraday drop, driven by a large active session. Volume surged to 2,033,000 shares versus an average of 193,941, giving a relative volume of 10.48. The move put liquidity and dilution risk in focus for IGEA Pharma N.V. (IGPH.SW). We use trading, fundamentals and sector context to explain the session and what it means for short- and medium-term holders.
Intraday action and trading metrics for IGPH.SW stock
IGPH.SW stock closed at CHF0.0015 after trading between CHF0.0015 and CHF0.0020 on the day. Volume was 2,033,000 shares, well above the 193,941 average, signalling the stock was among the most active on SIX. The one-day change logged -25.00% versus a previous close of CHF0.0020.
Fundamentals and valuation: IGPH.SW analysis
IGEA Pharma reports an EPS of -0.03 and a negative PE of -0.05, reflecting persistent losses. Market cap stands at CHF505,545 with 337,030,016 shares outstanding. Key ratios show a low current ratio of 0.19 and book value per share at -0.00713, underlining balance-sheet strain and thin liquidity.
Technical picture and trading profile for IGPH.SW stock
Short-term averages sit below long-term levels: the 50-day average is CHF0.00214 and the 200-day average is CHF0.00517. Relative volume of 10.48 highlights outsized intraday interest, but price has fallen 96.88% year-on-year. High volatility and low absolute price create execution and bid-ask risk for traders.
Meyka AI grade and model view in IGPH.SW analysis
Meyka AI rates IGPH.SW with a score out of 100: 61.95 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not investment advice.
Catalysts, product mix and IGPH.SW risks
IGEA Pharma sells diagnostic kits including Alz1 and other med-tech devices and operates in the Medical – Diagnostics & Research industry. Key risks are low cash per share (0.00009), one full-time employee, potential dilution and thin institutional coverage. Near-term catalysts would be confirmed revenue growth or clear financing without heavy dilution.
Sector context and peers in Healthcare for IGPH.SW stock outlook
The Healthcare sector on SIX shows an average PE of 32.59 and stronger liquidity among large peers like Roche and Novartis. IGPH.SW sits well below sector norms on scale and margins, which raises relative risk despite the sector’s defensive traits. Any re-rating would require consistent sales or a strategic deal.
Final Thoughts
IGPH.SW stock closed at CHF0.0015 on SIX on 06 Jan 2026 in the market closed session after heavy trading and a sharp intraday fall. The session highlighted extreme volatility: 2,033,000 shares changed hands and relative volume hit 10.48, creating short-term trading opportunities but also execution risk. Fundamentals remain challenged with EPS -0.03, negative book value per share, and a tiny market cap of CHF505,545, so capital raises and dilution are primary risks. Meyka AI’s forecast model projects a 12-month target of CHF0.0050, implying an upside of +233.33% from the current price of CHF0.0015; forecasts are model-based projections and not guarantees. Given the score 61.95 (B, HOLD) from Meyka AI, investors should treat IGPH.SW as a high-risk, speculative healthcare micro-cap and prioritise position sizing and liquidity checks before trading.
FAQs
The IGPH.SW stock fall to CHF0.0015 reflected heavy volume of 2,033,000 shares and low liquidity. The session’s large relative volume of 10.48 amplified selling pressure and highlighted short-term execution risk for small-cap healthcare stocks.
Meyka AI rates IGPH.SW with a score of 61.95, grade B and suggestion HOLD. The grade factors in benchmarks, sector and financial metrics and is informational, not financial advice.
Meyka AI’s forecast model projects a 12-month target of CHF0.0050 for IGPH.SW stock, implying a potential upside of +233.33% from CHF0.0015. Forecasts are model-based projections and not guarantees.
Key risks for IGPH.SW stock include balance-sheet strain, negative EPS, potential dilution, one full-time employee, and thin liquidity. These factors increase volatility and execution risk for holders and traders.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
